Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Proc Natl Acad Sci U S A
    December 2024
  1. VARUZHANYAN G, Chen CC, Freeland J, He T, et al
    PGC-1alpha drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
    Proc Natl Acad Sci U S A. 2024;121:e2416882121.
    >> Share

    November 2024
  2. KOHRT SE, Novak EJ, Tapadar S, Wu B, et al
    Small-molecule disruption of androgen receptor-dependent chromatin clusters.
    Proc Natl Acad Sci U S A. 2024;121:e2406239121.
    >> Share

    October 2024
  3. WANG Z, Yu H, Bao W, Qu M, et al
    Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
    Proc Natl Acad Sci U S A. 2024;121:e2402741121.
    >> Share

    September 2024
  4. SU XA, Stopsack KH, Schmidt DR, Ma D, et al
    RAD21 promotes oncogenesis and lethal progression of prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2405543121.
    >> Share

    August 2024
  5. YU G, Corn PG, Mak CSL, Liang X, et al
    Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
    Proc Natl Acad Sci U S A. 2024;121:e2402903121.
    >> Share

    July 2024
  6. PORNOUR M, Jeon HY, Ryu H, Khadka S, et al
    USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Proc Natl Acad Sci U S A. 2024;121:e2403331121.
    >> Share

  7. ZAIDI S, Park J, Chan JM, Roudier MP, et al
    Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Proc Natl Acad Sci U S A. 2024;121:e2322203121.
    >> Share

    April 2024
  8. HE T, Cheng C, Qiao Y, Cho H, et al
    Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2322563121.
    >> Share

    December 2023
  9. SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al
    Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
    Proc Natl Acad Sci U S A. 2023;120:e2312261120.
    >> Share

    November 2023
  10. MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al
    MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2307094120.
    >> Share

    August 2023
  11. WANG Z, Petricca J, Liu M, Zhang S, et al
    SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Proc Natl Acad Sci U S A. 2023;120:e2220472120.
    >> Share

    July 2023
  12. QIAO Y, Wotring JW, Zheng Y, Zhang CJ, et al
    Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
    Proc Natl Acad Sci U S A. 2023;120:e2221809120.
    >> Share

  13. CHEN X, Yang HT, Zhang B, Phillips JW, et al
    The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2023;120:e2220190120.
    >> Share

    May 2023
  14. SINGH R, Meng H, Shen T, Lumahan LEV, et al
    TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2218229120.
    >> Share

    April 2023
  15. ZHANG W, Lee AM, Jena S, Huang Y, et al
    Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.
    Proc Natl Acad Sci U S A. 2023;120:e2218522120.
    >> Share

    January 2023
  16. THIYAGARAJAN T, Ponnusamy S, Hwang DJ, He Y, et al
    Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2211832120.
    >> Share

    October 2022
  17. SHEN T, Dong B, Meng Y, Moore DD, et al
    A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205350119.
    >> Share

    September 2022
  18. SUN R, Wei T, Ding D, Zhang J, et al
    CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205509119.
    >> Share

    July 2022
  19. KORSEN JA, Gutierrez JA, Tully KM, Carter LM, et al
    Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2203820119.
    >> Share

    June 2022
  20. LEE J, Olivieri C, Ong C, Masterson LR, et al
    Raf Kinase Inhibitory Protein regulates the cAMP-dependent protein kinase signaling pathway through a positive feedback loop.
    Proc Natl Acad Sci U S A. 2022;119:e2121867119.
    >> Share

    May 2022
  21. BARATCHIAN M, Tiwari R, Khalighi S, Chakravarthy A, et al
    H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2114324119.
    >> Share

    April 2022
  22. VAN HEIJSTER FHA, Breukels V, Jansen KCFJ, Schalken JA, et al
    Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.
    Proc Natl Acad Sci U S A. 2022;119:e2024357119.
    >> Share

    January 2022
  23. BAKHT MK, Hayward JJ, Shahbazi-Raz F, Skubal M, et al
    Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2022;119.
    >> Share

  24. LIAO Y, Chen CH, Xiao T, de la Pena Avalos B, et al
    Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
    Proc Natl Acad Sci U S A. 2022;119.
    >> Share

    October 2021
  25. BELLO T, Paindelli C, Diaz-Gomez LA, Melchiorri A, et al
    Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    >> Share

    September 2021
  26. YOSHIHAMA Y, LaBella KA, Kim E, Bertolet L, et al
    AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.
    Proc Natl Acad Sci U S A. 2021;118.
    >> Share

    August 2021

  27. Correction for Baek et al., Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2021;118.
    >> Share

  28. SHRESTHA E, Coulter JB, Guzman W, Ozbek B, et al
    Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    >> Share

  29. FENG W, Cao Z, Lim PX, Zhao H, et al
    Rapid interrogation of cancer cell of origin through CRISPR editing.
    Proc Natl Acad Sci U S A. 2021;118.
    >> Share

    March 2021
  30. WU WF, Wang L, Spetsieris N, Boukovala M, et al
    Estrogen receptor beta and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
    Proc Natl Acad Sci U S A. 2021;118:e2011269118.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016